<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>144</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001688319</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>


    </filerInfo>
  </headerData>
  <formData>
    <issuerInfo>
      <issuerCik>0001603454</issuerCik>
      <issuerName>Celcuity Inc.</issuerName>
      <secFileNumber>001-38207</secFileNumber>
      <issuerAddress>
        <com:street1>16305 36TH AVENUE N</com:street1>
        <com:street2>SUITE 100</com:street2>
        <com:city>MINNEAPOLIS</com:city>
        <com:stateOrCountry>MN</com:stateOrCountry>
        <com:zipCode>55446</com:zipCode>
      </issuerAddress>
      <issuerContactPhone>763-392-0767</issuerContactPhone>
      <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>Buller Richard E</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
      <relationshipsToIssuer>
        <relationshipToIssuer>Director</relationshipToIssuer>
      </relationshipsToIssuer>
    </issuerInfo>
    <securitiesInformation>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <brokerOrMarketmakerDetails>
        <name>Stifel Nicolaus &amp; Company Inc</name>
        <address>
          <com:street1>501 N Broadway</com:street1>
          <com:city>St. Louis</com:city>
          <com:stateOrCountry>MO</com:stateOrCountry>
          <com:zipCode>63102</com:zipCode>
        </address>
      </brokerOrMarketmakerDetails>
      <noOfUnitsSold>6000</noOfUnitsSold>
      <aggregateMarketValue>661607.00</aggregateMarketValue>
      <noOfUnitsOutstanding>48336675</noOfUnitsOutstanding>
      <approxSaleDate>03/31/2026</approxSaleDate>
      <securitiesExchangeName> Nasdaq </securitiesExchangeName>
    </securitiesInformation>
    <securitiesToBeSold>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <acquiredDate>05/14/2020</acquiredDate>
      <natureOfAcquisitionTransaction> Option Exercise </natureOfAcquisitionTransaction>
      <nameOfPersonfromWhomAcquired> Issuer </nameOfPersonfromWhomAcquired>
      <isGiftTransaction>N</isGiftTransaction>
      <amountOfSecuritiesAcquired>6000</amountOfSecuritiesAcquired>
      <paymentDate>03/31/2026</paymentDate>
      <natureOfPayment>Equity Compensation</natureOfPayment>
    </securitiesToBeSold>
    <nothingToReportFlagOnSecuritiesSoldInPast3Months>Y</nothingToReportFlagOnSecuritiesSoldInPast3Months>
    <remarks>Shares sold pursuant to a Rule 10b5-1 Plan via Oncology Diagnostic &amp; Drug Development Consulting LLC</remarks>
    <noticeSignature>
      <noticeDate>03/31/2026</noticeDate>
      <planAdoptionDates>
        <planAdoptionDate>12/08/2025</planAdoptionDate>
      </planAdoptionDates>
      <signature>/s/ James Weimer, as a duly authorized representative of STIFEL, as attorney-in-fact for Richard Buller</signature>
    </noticeSignature>
  </formData>
</edgarSubmission>
